Neuralstem (CUR) : During the past 4 weeks, traders have been relatively bearish on Neuralstem (CUR), hence the stock is down -24.08% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -10.18% relative to the S&P 500. The 4-week change in the price of the stock is -23.3% and the stock has fallen -10.14% in the past 1 week.
The stock has recorded a 20-day Moving Average of 16.53% and the 50-Day Moving Average is 28.7%. Neuralstem (NASDAQ:CUR): On Fridays trading session , Opening price of the stock was $0.219 with an intraday high of $0.23. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.19. However, the stock managed to close at $0.1995, a loss of 9.28% for the day. On the previous day, the stock had closed at $0.2199. The total traded volume of the day was 1,230,925 shares.
The company Insiders own 19.25% of Neuralstem shares according to the proxy statements. Institutional Investors own 12.52% of Neuralstem shares.
Neuralstem, Inc. (Neuralstem) is engaged in development and commercialization of regenerative medicine treatments based on its human neuronal stem cells and its small molecule compounds. Neuralstems technology enables the isolation and expansion of human neural stem cells from all areas of the developing human brain and spinal cord, thus enabling the generation of physiologically relevant human neurons of all types. It has developed and patented a series of small molecule compounds. The Company is developing products using technology, including Cell Therapy and Small Molecule Pharmaceutical Compounds. The Company has a wholly owned subsidiary, Suzhou Sun-Now Biopharmaceutical Co. Ltd. in China. Its clinical programs include the NSI-566 and NSI-189.